Skip to content
Screener

Tectonic Therapeutics TECX Financing Cash Flow

Financing Cash Flow at other companies

ALN
Alnylam PharmaceuticalsALNY
$36.24M-32.6%
Septerna, Inc. logo
Septerna, Inc.SEPN
$16.82M+4,863%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$21K-98.4%
Regenxbio logo
RegenxbioRGNX
$17.57M-87.4%
Opko Health logo
Opko HealthOPK
-$13.03M+83.6%
Celcuity logo
CelcuityCELC
$34K-99.4%

Other financials

Income statement

See full
Operating income-$27.3M-49.2%
Net income-$25.2M-58.7%
EPS (diluted)-$1.34-44.1%

Balance sheet

See full
Cash & equivalents$236.9M-22.8%
Total debt$4.9M+86.1%
Total equity$230.4M-23.5%
Total assets$246.6M-21.7%

Cash flow

See full
Operating cash flow-$18.4M-40.7%
CapEx$19.0K-29.6%
Free cash flow-$18.4M-40.6%

Valuation

See full
Market cap$639.46M+54.6%
Enterprise value$407.46M+219%

Returns & leverage

See full
Return on equity-31.4%
Debt / equity0.0×
Current ratio18.5×-4.4×

Where this comes from

Reported directly by Tectonic Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Tectonic Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:19 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-212016
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from exercise of stock options100972
Payments for employee taxes related to net share settlement of equity awards(412)
Repayment of finance lease obligations(105)(118)
Net cash provided by financing activities847178,122
Effect of exchange rate changes on cash and cash equivalents94(5)
Net (decrease) increase in cash and cash equivalents and restricted cash(17,491)165,007
Cash and cash equivalents and restricted cash as of beginning of period254,870141,826
Cash and cash equivalents and restricted cash as of end of period$237,379$306,833

Item 1. Financial Statements.

FAQ

What is Tectonic Therapeutics's financing cash flow?
Tectonic Therapeutics (TECX) reported financing cash flow of $847K in Q1 2026.
How has Tectonic Therapeutics's financing cash flow changed year-over-year?
Tectonic Therapeutics's financing cash flow decreased by 99.5% year-over-year, from $178.12M to $847K.
What is the long-term trend for Tectonic Therapeutics's financing cash flow?
Over 2 years (2021 to 2023), Tectonic Therapeutics's financing cash flow has grown at a 5.4% compound annual growth rate (CAGR), from $30.37M to $33.75M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Tectonic Therapeutics's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude